Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BiomX Presenting at Three Upcoming Investor Conferences

2022 Aegis Virtual Conference on February 24, 2022

Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022

Oppenheimer & Co. 32nd Annual Virtual Healthcare Conference on March 17, 2022

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17, 2022.

2022 Aegis Virtual Conference – February 23-25, 2022

 

 

Date & Time:

Thursday, March 24, 2:30 PM EST

Presenter:

Jonathan Solomon

Conference registration:

Link

 

Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022

 

 

Date & Time:

Tuesday, March 1, 8:30 AM EST

Presenter:

Conference registration:

Jonathon Solomon

Link

 

Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022

 

 

Date & Time:

Thursday, March 17, 2:00 PM EST

Presenter:

Jonathan Solomon

Conference registration:

Link

Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.

About BiomX Inc.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.